Review of Systemic Immunosuppression for Autoimmune Uveitis

Claudia P. Castiblanco, C. Stephen Foster

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The purpose of this review is to comprehensively examine the various therapeutic agents available to treat autoimmune eye disease, their indications, clinical safety and recent developments. The stepladder approach is reviewed, including corticosteroid administration of various forms, classic immunomodulators, and newer biologic response modifiers. The authors present that corticosteroid monotherapy is almost never curative and carries significant side effects, while immunomodulatory therapy, when used appropriately as way to induce steroid-free remission, carries far less risk of causing long-term complications and provides greater potential of altering the immune system to induce a durable remission.

Original languageEnglish (US)
Pages (from-to)17-36
Number of pages20
JournalOphthalmology and Therapy
Volume3
Issue number1-2
DOIs
StatePublished - Dec 4 2014
Externally publishedYes

Fingerprint

Uveitis
Immunosuppression
Adrenal Cortex Hormones
Immunomodulation
Eye Diseases
Immunologic Factors
Autoimmune Diseases
Immune System
Steroids
Safety
Therapeutics

Keywords

  • Corticosteroid
  • Immunomodulatory therapy
  • Inflammation
  • Ophthalmology
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Review of Systemic Immunosuppression for Autoimmune Uveitis. / Castiblanco, Claudia P.; Foster, C. Stephen.

In: Ophthalmology and Therapy, Vol. 3, No. 1-2, 04.12.2014, p. 17-36.

Research output: Contribution to journalReview article

@article{98b8b88b541642a5b20e93e1221cb6c1,
title = "Review of Systemic Immunosuppression for Autoimmune Uveitis",
abstract = "The purpose of this review is to comprehensively examine the various therapeutic agents available to treat autoimmune eye disease, their indications, clinical safety and recent developments. The stepladder approach is reviewed, including corticosteroid administration of various forms, classic immunomodulators, and newer biologic response modifiers. The authors present that corticosteroid monotherapy is almost never curative and carries significant side effects, while immunomodulatory therapy, when used appropriately as way to induce steroid-free remission, carries far less risk of causing long-term complications and provides greater potential of altering the immune system to induce a durable remission.",
keywords = "Corticosteroid, Immunomodulatory therapy, Inflammation, Ophthalmology, Uveitis",
author = "Castiblanco, {Claudia P.} and Foster, {C. Stephen}",
year = "2014",
month = "12",
day = "4",
doi = "10.1007/s40123-014-0023-x",
language = "English (US)",
volume = "3",
pages = "17--36",
journal = "Ophthalmology and Therapy",
issn = "2193-8245",
publisher = "Springer London",
number = "1-2",

}

TY - JOUR

T1 - Review of Systemic Immunosuppression for Autoimmune Uveitis

AU - Castiblanco, Claudia P.

AU - Foster, C. Stephen

PY - 2014/12/4

Y1 - 2014/12/4

N2 - The purpose of this review is to comprehensively examine the various therapeutic agents available to treat autoimmune eye disease, their indications, clinical safety and recent developments. The stepladder approach is reviewed, including corticosteroid administration of various forms, classic immunomodulators, and newer biologic response modifiers. The authors present that corticosteroid monotherapy is almost never curative and carries significant side effects, while immunomodulatory therapy, when used appropriately as way to induce steroid-free remission, carries far less risk of causing long-term complications and provides greater potential of altering the immune system to induce a durable remission.

AB - The purpose of this review is to comprehensively examine the various therapeutic agents available to treat autoimmune eye disease, their indications, clinical safety and recent developments. The stepladder approach is reviewed, including corticosteroid administration of various forms, classic immunomodulators, and newer biologic response modifiers. The authors present that corticosteroid monotherapy is almost never curative and carries significant side effects, while immunomodulatory therapy, when used appropriately as way to induce steroid-free remission, carries far less risk of causing long-term complications and provides greater potential of altering the immune system to induce a durable remission.

KW - Corticosteroid

KW - Immunomodulatory therapy

KW - Inflammation

KW - Ophthalmology

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84914670823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914670823&partnerID=8YFLogxK

U2 - 10.1007/s40123-014-0023-x

DO - 10.1007/s40123-014-0023-x

M3 - Review article

AN - SCOPUS:84914670823

VL - 3

SP - 17

EP - 36

JO - Ophthalmology and Therapy

JF - Ophthalmology and Therapy

SN - 2193-8245

IS - 1-2

ER -